Jazz Pharmaceuticals (JAZZ)
(Delayed Data from NSDQ)
$109.04 USD
-2.37 (-2.13%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $109.52 +0.48 (0.44%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$109.04 USD
-2.37 (-2.13%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $109.52 +0.48 (0.44%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
Zacks News
Can Zymeworks (ZYME) Beat Expectations This Earnings Season?
by Zacks Equity Research
In the absence of a marketed product, Zymeworks (ZYME) is expected to provide an update on its pipeline candidates, mainly zanidatamab for the treatment of patients with HER2-expressing cancers, at the fourth-quarter conference call.
Catalent (CTLT) Misses Q2 Earnings Estimates
by Zacks Equity Research
Catalent (CTLT) delivered earnings and revenue surprises of -6.94% and 2.41%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Catalyst (CPRX): Can Its 9.2% Jump Turn into More Strength?
by Zacks Equity Research
Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Jazz (JAZZ) Gastric Cancer Study Shows Improved Overall Survival
by Zacks Equity Research
Jazz (JAZZ) reports data from a mid-stage study on its investigational bispecific antibody targeting HER2-expressing mGEA. The treatment achieved an overall survival rate of 84% in 18 months.
Axsome (AXSM) Rides on New Drug Approval & Sunosi Buyout
by Zacks Equity Research
Axsome (AXSM) receives FDA approval for Auvelity to treat major depressive disorder in August. The Sunosi deal and promising pipeline bode well. Stiff competition in the target market remains a woe.
Zymeworks (ZYME) Stock Up 29% in Three Months: Here's Why
by Zacks Equity Research
Zymeworks (ZYME) recently entered a collaboration with Jazz Pharmaceuticals (JAZZ) for its lead pipeline candidate. This has been a significant catalyst for the stock.
Zymeworks (ZYME) Up After Jazz Exercises Option for Cancer Drug
by Zacks Equity Research
Following positive data from a mid-stage study evaluating Zymeworks' (ZYME) lead candidate, Jazz (JAZZ) exercises its option to acquire the rights to develop and market this candidate.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Are Options Traders Betting on a Big Move in Jazz Pharmaceuticals (JAZZ) Stock?
by Zacks Equity Research
Investors need to pay close attention to Jazz Pharmaceuticals (JAZZ) stock based on the movements in the options market lately.
Why Is Jazz (JAZZ) Up 0.1% Since Last Earnings Report?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jazz Pharma's (JAZZ) Gets FDA Nod for Rylaze's New Dosing Option
by Zacks Equity Research
Jazz Pharma (JAZZ) gets FDA approval for an MWF intramuscular (IM) dosing schedule for Rylaze to treat acute lymphoblastic leukemia or lymphoblastic lymphoma with hypersensitivity to asparaginase.
Implied Volatility Surging for Jazz Pharmaceuticals (JAZZ) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Jazz Pharmaceuticals (JAZZ) stock based on the movements in the options market lately.
Catalyst's (CPRX) Q3 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Catalyst's (CPRX) earnings and revenues beat estimates for the third quarter of 2022. The company increases the full-year revenue guidance.
Jazz's (JAZZ) Q3 Earnings Beat Estimates, New Drugs Drive Sales
by Zacks Equity Research
Jazz's Q3 earnings and sales beat expectations on strong demand for new drugs and drugs added with the GW Pharmaceuticals acquisition. The company raises the mid-point of its 2022 sales guidance.
Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Jazz (JAZZ) delivered earnings and revenue surprises of 9.53% and 0.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Axsome (AXSM) Q3 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Axsome (AXSM) reports a narrower-than-expected loss in the third quarter. Revenues comprise sales of the sleep drug, Sunosi, acquired from Jazz.
Why Jazz Pharmaceuticals (JAZZ) Might Surprise This Earnings Season
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Catalyst Pharmaceuticals (CPRX) to Post Q3 Earnings: What's Up?
by Zacks Equity Research
On Catalyst Pharmaceuticals' (CPRX) third-quarter earnings call, investors will likely focus on the sales performance of Firdapse approved for treating LEMS.
Pacira's (PCRX) Q3 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Pacira's (PCRX) earnings fall shy of estimates in the third quarter of 2022 while revenues beat the same.
Corcept's (CORT) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Corcept's (CORT) third-quarter 2022 earnings beat estimates while revenues miss the same. The company tightens its revenue guidance for 2022. Shares down in after-hours trading.
Can Cigna's (CI) Q3 Earnings Beat on Evernorth Performance?
by Zacks Equity Research
The third-quarter results of Cigna (CI) are likely to reflect a rise in total medical customers.
Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cassava Sciences (SAVA) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Cassava Sciences (SAVA) is expected to provide an update on its pipeline candidates during its third-quarter earnings.
Viatris (VTRS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Viatris (VTRS) Q3 results are likely to be impacted by foreign exchange rate fluctuations. An update on the deal with Biocon is also expected along with the results.
Zoetis (ZTS) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Zoetis (ZTS) is anticipated to report positive earnings and revenues for third-quarter 2022. It will also provide an update on its pipeline on the earnings call.